As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China ...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received the approval from the U.S. Food and Drug ...